Factor vii deficiency diagnosis and management
Sponsored Links
This presentation is the property of its rightful owner.
1 / 13

Factor VII Deficiency Diagnosis and Management PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

Factor VII Deficiency Diagnosis and Management. Hamid Hoorfar MD Inherited Blood Disorders Clinic Esfahan Medical Sciences University 2014. Introduction. Factor VII is a vit K dependent clotting factor belonging to the extrinsic pathway.( serocovertin , stable factor)

Download Presentation

Factor VII Deficiency Diagnosis and Management

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Factor VII DeficiencyDiagnosis and Management

Hamid Hoorfar MD

Inherited Blood Disorders Clinic

Esfahan Medical Sciences University



Factor VII is a vit K dependent clotting factor belonging to the extrinsic pathway.( serocovertin , stable factor)

FVII is a protein with 406 AA single chain ( 50 kDa).

In the bloodtreamFVIIa is the active portion of the FVII mass and is detectable in normal concentration as low as 5-10 ng.(1-2% of zymogen)

The factor VII gen is located on chromosome 13 upstream of factor X and contains 9 exons.

Congenital factor VII Deficiency

The bleeding disorder was first described by Alexander in 1951.

Congenital FVII deficiency is the commonest among the rare inherited bleeding disorders with prevalence of 1 in 500000 individual.

It is an autosomal recessive disease . Bleedings is uncommon in FVII heterozygotes.

Complete absence of functional FVII is incompatible with life.

Numerous mutations underlying the disease have been described , which are predictive for a considerable heterogeneity in both clotting and clinical phenotypes.

Missense are most frequent mutations (70 -80%)

Clinical manifestations

Heterozygotes are usually asymptomatic while homozygotes and compound heterozygotes are develop hemorrhagic tendency.

Age and type of first bleeding are variables and correlate with clinical severity.

Bleeding symptoms ranging from severe to mild or even asymptomatic forms as the activity of Factor VII does not correlate well with bleeding tendency.

IRF7 research group proposed the classification of bleeding phenotype as hemophilia like , platelet like & asymptomatic.

ICH, GI and joint bleeds classified as severe bleedings associated with FVII levels < 5IU/dl ,without a clear relationship to the type of gene defect.

Menorrhagia is a very frequent type of bleeding in women with F7 deficiency (63%)

Clinical manifestationsIRF7 database (228 patients)

Clinical manifestationsIRF7 database (174 female)

Diagnosis of Factor VII deficiency

Prolonged PT from moderate to markedly prolonged and normal PTT

FVIIc is the confirmatory test for diagnosis

Factor VII deficiency has been found to be associated with hepatic congenital enzymic defects ( dubin – johnson and gilbert syndromes)

Only 51.4% of subjects with Factor VII deficiency were diagnosed within 6 months after the first symptoms.

Treatment of bleeding in FVII deficiency

Prevention and treatment of bleeding resides in the replacement of the missing factor.

Because of short biological half life of FVII repeated administration every 6-8 hours is needed.

FFP, Prothrombin complex(PCC), plasma derived FVII concentrate and recombinant FVIIaavailable options.

Factor VIIa is today considered the first line product for replacement therapy in FVII deficiency .

Treatment materials for congenital FVII deficiency

Surgery in FVII deficiency

Several reports on surgical intervention under FVII replacement have been published.

A FVII level between 10-15IU/dl considered to be heamostatic level.

Neither a true minimum level nor the optimum duration of factor substitution are well known.

In the STER study have been shown that postoperative haemostatic can be secured by rFVII a at a dose of at least 13μg/kg 3 times/day.

In patients with FVII level < 1 IU/dl the mean duration postoperative replacement was 5.8 .

از توجه شما سپاسگزارم

  • Login